{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:42:58Z","timestamp":1769161378737,"version":"3.49.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-A-194"],"award-info":[{"award-number":["2022-PUMCH-A-194"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00277-023-05390-4","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T11:01:57Z","timestamp":1690801317000},"page":"2973-2975","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases"],"prefix":"10.1007","volume":"102","author":[{"given":"Yupeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1192-4896","authenticated-orcid":false,"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,31]]},"reference":[{"issue":"1","key":"5390_CR1","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.4081\/hr.2010.e5","volume":"2","author":"X Ort\u00edn","year":"2010","unstructured":"Ort\u00edn X, Rodr\u00edguez-Luaces M, Bosch R, Lejeune M, Font L (2010) Acute liver failure as the first manifestation of very late relapsing of Hodgkin\u2019s disease. Hematol Rep 2(1):e5. https:\/\/doi.org\/10.4081\/hr.2010.e5","journal-title":"Hematol Rep"},{"issue":"6","key":"5390_CR2","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1016\/s2352-3026(21)00102-2","volume":"8","author":"DJ Straus","year":"2021","unstructured":"Straus DJ, D\u0142ugosz-Danecka M, Connors JM, Alekseev S, Ill\u00e9s \u00c1, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Munoz J, Lee HJ, Kim WS, Advani R et al (2021) Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol 8(6):e410\u2013e421. https:\/\/doi.org\/10.1016\/s2352-3026(21)00102-2","journal-title":"Lancet Haematol"},{"issue":"26","key":"5390_CR3","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","volume":"126","author":"A Forero-Torres","year":"2015","unstructured":"Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, Bordoni RE, Friedberg JW, Sharman JP, Palanca-Wessels MC, Wang Y, Yasenchak CA (2015) Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood 126(26):2798\u20132804. https:\/\/doi.org\/10.1182\/blood-2015-06-644336","journal-title":"Blood"},{"issue":"2","key":"5390_CR4","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.clml.2015.11.015","volume":"16","author":"A Gupta","year":"2016","unstructured":"Gupta A, Petrasek J, Sen S, Gopal P, Naina HV (2016) Single-agent brentuximab as bridging therapy for Hodgkin lymphoma patients with hepatic impairment. Clin Lymphoma Myeloma Leuk 16(2):e11\u2013e14. https:\/\/doi.org\/10.1016\/j.clml.2015.11.015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"5390_CR5","first-page":"2483","volume":"24","author":"N Spathas","year":"2019","unstructured":"Spathas N, Belia M, Giannikos T, Arapaki M, Efstathopoulou M, Tsourouflis G, Gainaru G, Asimakopoulos J, Tsaftaridis P, Angelopoulou MK, Plata E, Konstantopoulos K, Theodoros PV (2019) Successful reversal of severe liver function impairment with brentuximab vedotin in multiply relapsed\/refractory classical Hodgkin lymphoma. J buon 24(6):2483\u20132489","journal-title":"J buon"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05390-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05390-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05390-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T10:05:52Z","timestamp":1694253952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05390-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,31]]},"references-count":5,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["5390"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05390-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,31]]},"assertion":[{"value":"7 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants performed by any of the authors (and\/or in case humans were involved). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from both patients for being included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}